Unknown

Dataset Information

0

[Valproic Acid Could Help in the Fight Against COVID-19: a case-control study].


ABSTRACT: There is early evidence about Valproic acid (VPA) antiviral effect. Our aim was to investigate the incidence and severity of SARS-CoV-2 infection in VPA users as compared with the general population. A case-control study nested within a cohort, carried out between March 1 and December 17, 2020. Retrospectively, we identified confirmed SARS-CoV-2 infection patients exposed to VPA in our health department (defined as case). We ascertained VPA regimen (all the time (AT)(292 days) or at least 20% of the study period (notAT)(≥58 days) and if VPA levels were in therapeutic range (ATR) (50-100 mcg/mL) in the last 24 months. We calculated the cumulative incidence of SARS-CoV-2 infection and hospital admission in the cases, comparing it with the general unexposed VPA population (controls). During the study period, 6183 PCR+ were detected among 281035 inhabitants, of these, 746 were hospitalized. 691 patients were on VPA notAT and 628 (90.1%) AT. The indication for VPA use was epilepsy in 54.9%. The incidence of PCR+ was 1.736 % (OR 0.785 (95%CI 0.443-1.390) and 1.910 % (OR 0.865 (95%CI 0.488-1.533), on VPA notAT and VPA AT patients, respectively vs. 2.201% in people without VPA regimen. Those patients with VPA ATR had a lower risk of PCR + (OR 0.233 (95%CI 0.057-0.951) notAT; OR 0.218 (95%CI 0.053-0.890) AT). Hospital admission incidence was lower in patient on VPA (OR was 0.543 (95% CI 0.076 to 3.871). Patients with VPA within the therapeutic range had a reduction of SARS-Cov-2 infection incidence greater than 75%. There is a downward trend in the risk of COVID-19 admission by SARS-CoV-2 in patients on VPA therapy. These findings warrant further investigation.

SUBMITTER: Moreno-Perez O 

PROVIDER: S-EPMC8841207 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Objective</h4>There is early evidence about Valproic acid (VPA) antiviral effect. Our aim was to investigate the incidence and severity of SARS-CoV-2 infection in VPA users as compared with the general population.<h4>Material and methods</h4>A case-control study nested within a cohort, carried out between March 1 and December 17, 2020. Retrospectively, we identified confirmed SARS-CoV-2 infection patients exposed to VPA in our health department (defined as case). We ascertained VPA regimen (  ...[more]

Similar Datasets

| S-EPMC7323198 | biostudies-literature
| S-EPMC7704938 | biostudies-literature
| S-EPMC8227143 | biostudies-literature
| S-EPMC7202852 | biostudies-literature
| S-EPMC7218351 | biostudies-literature
| S-EPMC9220020 | biostudies-literature
| S-EPMC8552549 | biostudies-literature
| S-EPMC11770277 | biostudies-literature
| S-EPMC10669926 | biostudies-literature
| S-EPMC10551991 | biostudies-literature